StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$7.00−0.07 (-0.99%)

Close on Nov 19, 2026Market cap $462.35MP/E –Yield –

Evolus shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Evolus's shares outstanding was 66M at Jun 30, 2026. For fiscal 2025 it was 64M, up 4.0% from the year before. The highest annual figure on record is 64M in fiscal 2025.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 202564M+4.0%
FY2024Dec 31, 202462M+9.0%
FY2023Dec 31, 202357M+1.5%
FY2022Dec 31, 202256M+12.6%
FY2021Dec 31, 202150M+47.5%
FY2020Dec 31, 202034M+19.5%
FY2019Dec 31, 201928M+15.7%
FY2018Dec 31, 201824M+47.7%
FY2017Dec 31, 201717M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 202666M+2.2%
Q1 FY2026Mar 31, 202665M+2.3%
Q4 FY2025Dec 31, 202565M+2.4%
Q3 FY2025Sep 30, 202565M+2.5%
Q2 FY2025Jun 30, 202565M+2.9%
Q1 FY2025Mar 31, 202564M+8.3%
Q4 FY2024Dec 31, 202463M+10.7%
Q3 FY2024Sep 30, 202463M+10.7%
Q2 FY2024Jun 30, 202463M+10.2%
Q1 FY2024Mar 31, 202459M+4.1%
Q4 FY2023Dec 31, 202357M+1.7%
Q3 FY2023Sep 30, 202357M+1.5%
Q2 FY2023Jun 30, 202357M+1.5%
Q1 FY2023Mar 31, 202356M+1.3%
Q4 FY2022Dec 31, 202256M+1.1%
Q3 FY2022Sep 30, 202256M+2.1%
Q2 FY2022Jun 30, 202256M+9.6%
Q1 FY2022Mar 31, 202256M+35.6%
Q4 FY2021Dec 31, 202156M+64.9%
Q3 FY2021Sep 30, 202155M+63.0%
Q2 FY2021Jun 30, 202151M+51.6%
Q1 FY2021Mar 31, 202141M+21.9%
Q4 FY2020Dec 31, 202034M+9.8%
Q3 FY2020Sep 30, 202034M+22.9%
Q2 FY2020Jun 30, 202034M+23.1%
Q1 FY2020Mar 31, 202034M+23.4%
Q4 FY2019Dec 31, 201931M+12.4%
Q3 FY2019Sep 30, 201927M+10.9%
Q2 FY2019Jun 30, 201927M+15.7%
Q1 FY2019Mar 31, 201927M+35.1%
Q4 FY2018Dec 31, 201827M+65.5%
Q3 FY2018Sep 30, 201825M+49.9%
Q2 FY2018Jun 30, 201824M+43.3%
Q1 FY2018Mar 31, 201820M+22.4%
Q4 FY2017Dec 31, 201717M–
Q3 FY2017Sep 30, 201717M–
Q2 FY2017Jun 30, 201717M–
Q1 FY2017Mar 31, 201717M–

More Evolus figures

See a number that looks wrong?